Literature DB >> 7690810

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

C G Ioannides1, B Fisk, K R Jerome, T Irimura, J T Wharton, O J Finn.   

Abstract

CTL isolated from tumor infiltrating lymphocytes/tumor associated lymphocytes (TAL) infiltrating ovarian tumors have been demonstrated to mediate lysis of tumor targets after in vitro culture. These effector cells are of particular interest as cellular probes to detect and define human tumor Ag and epitopes that stimulate cellular immunity to human tumors. Polymorphic epithelial mucin (PEM) core peptides are potential candidates as tumor specific Ag because of their preferential expression on epithelial tumors. We report here that ovarian CTL-TAL can recognize mucin (Muc-1) core peptide of PEM. Several ovarian CTL-TAL lines were developed that recognized in a non-MHC restricted fashion an Muc-1+ ovarian tumor, but not Muc-1-tumor. To define the specificity of these CTL-TAL and exclude cross-reactivity with other potential Ag, cytotoxicity experiments were performed using as targets EBV-transformed cell lines with an expression construct containing the Muc.1 cDNA. These ovarian CTL-TAL lysed mucin core-peptide transfected cells but not targets transfected with an expression construct containing a mucin frame-shift mutant cDNA as control. In addition, targets pulsed with short synthetic peptides composed of amino acids 1-14 of the Muc 1 core peptide repeat were also lysed by the same CTL-TAL. This lysis was inhibited by the mAb SM3 that recognize an epitope on the mucin core peptide. These results, which are a demonstration of a specific Ag recognized by ovarian CTL-TAL, may be of interest for specific immunotherapy of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690810

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma.

Authors:  M V Croce; M E Rabassa; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 3.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 4.  Epidemiologic perspective on immune-surveillance in cancer.

Authors:  Daniel W Cramer; Olivera J Finn
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

5.  Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Catherine A Phillips; Mary Townsend; Ramila Philip; Mark J Dobrzanski; Pamela R Lockwood-Cooke; William Robinson
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

6.  Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.

Authors:  Brigitte Gückel; Christine Rentzsch; Maria-Dorothea Nastke; Alexander Marmé; Ines Gruber; Stefan Stevanović; Simone Kayser; Diethelm Wallwiener
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-22       Impact factor: 4.553

7.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 9.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

10.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.

Authors:  G Pecher; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.